Tenaya CEO sells shares to cover RSU taxes

Tenaya Therapeutics Chief Executive Officer Ali Faraz reported an open-market sale of 3,390 shares of common stock at $0.7934 per share on May 18, 2026.

Rhea-AI Filing Summary

Tenaya Therapeutics Chief Executive Officer Ali Faraz reported an open-market sale of 3,390 shares of common stock at $0.7934 per share on May 18, 2026. According to the footnotes, the shares were sold to cover tax withholding obligations related to vesting restricted stock units awarded on February 6, 2025.

After this transaction, Faraz directly holds 440,014 shares of Tenaya Therapeutics common stock. The holding figure includes 321,581 shares that will be issued upon future vesting of restricted stock units, underscoring that the reported sale is tied to tax obligations rather than a reduction of long-term equity awards.

Insider Trade Summary

Net Seller: 3,390 shares

Net Sell 1 txn

Insider Ali Faraz

Role Chief Executive Officer

Sold 3,390 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,390	$0.7934	$3K

Holdings After Transaction: Common Stock — 440,014 shares (Direct)

Footnotes (2)

1. F1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.
2. F2. Includes 321,581 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

Key Figures

Shares sold: 3,390 shares Sale price per share: $0.7934 per share Shares held after transaction: 440,014 shares +1 more

4 metrics

Shares sold 3,390 shares Open-market sale on May 18, 2026

Sale price per share $0.7934 per share Price for the 3,390 shares sold

Shares held after transaction 440,014 shares Common stock directly held following the sale

RSU-linked shares included in holdings 321,581 shares To be issued upon vesting of restricted stock units

Key Terms

restricted stock units, open-market sale, tax withholding obligations

3 terms

restricted stock units financial

"vesting of restricted stock units awarded on February 6, 2025"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action":"open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax withholding obligations financial

"Shares sold to cover tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tenaya Therapeutics (TNYA) disclose for Ali Faraz?

Tenaya Therapeutics disclosed that CEO Ali Faraz sold 3,390 shares of common stock at $0.7934 per share. The sale occurred on May 18, 2026 and was reported as an open-market transaction on Form 4 filed with regulators.

Why did Tenaya Therapeutics CEO Ali Faraz sell 3,390 TNYA shares?

The 3,390 shares sold by CEO Ali Faraz were used to cover tax withholding obligations. These obligations arose from the vesting of restricted stock units granted on February 6, 2025, according to the footnote describing the purpose of the sale.

How many Tenaya Therapeutics shares does Ali Faraz hold after this Form 4 sale?

After the sale, Ali Faraz holds 440,014 shares of Tenaya Therapeutics common stock. This total includes shares currently held and 321,581 additional shares that will be issued to him upon the vesting of outstanding restricted stock units noted in the disclosure.

At what price were the Tenaya Therapeutics shares sold in Ali Faraz’s Form 4 filing?

The reported sale price was $0.7934 per share for the 3,390 Tenaya Therapeutics shares. This per-share price is specifically disclosed as the transaction price in the Form 4, reflecting the consideration received in the open-market sale used for tax withholding.

How many restricted stock unit shares are included in Ali Faraz’s Tenaya Therapeutics holdings?

Ali Faraz’s holdings include 321,581 shares of Tenaya Therapeutics common stock that will be issued upon vesting of restricted stock units. This figure is explicitly identified in a footnote explaining that these shares are tied to outstanding RSU awards that vest over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 07:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Faraz

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		S(1)		3,390	D	$0.7934	440,014(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

2. Includes 321,581 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)